Lethal pneumonitis after docetaxel chemotherapy: Case report and review of the literature

References

• Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. Ctcae v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176–81.
   PubMed Web of Science ®Google Scholar
• Min BD, Kang HW, Kim WT, Kim YJ, Yun SJ, Lee SC, et al. Docetaxel-induced fatal interstitial pneumonitis in a patient with castration-resistant prostate cancer. Korean J Urol 2012;53:371–4.
   PubMedGoogle Scholar
• Nagata S, Ueda N, Yoshida Y, Matsuda H, Maehara Y. Severe interstitial pneumonitis associated with the administration of taxanes. J Infect Chemother 2010;16:340–4.
   PubMed Web of Science ®Google Scholar
• Read WL, Mortimer JE, Picus J. Severe interstitial pneumonitis associated with docetaxel administration. Cancer 2002; 94:847–53.
   PubMed Web of Science ®Google Scholar
• Merad M, Le Cesne A, Baldeyrou P, Mesurolle B, Le Chevalier T. Docetaxel and interstitial pulmonary injury. Ann Oncol 1997;8:191–4.
   PubMed Web of Science ®Google Scholar
• Muller NL, White DA, Jiang H, Gemma A. Diagnosis and management of drug-associated interstitial lung disease. Br J Cancer 2004;91(Suppl 2):S24–30.
   Web of Science ®Google Scholar
• Rossi SE, Erasmus JJ, McAdams HP, Sporn TA, Goodman PC. Pulmonary drug toxicity: Radiologic and pathologic manifestations. Radiographics 2000;20: 1245–59.
   PubMed Web of Science ®Google Scholar
• Dang C, D’Andrea G, Lake D, Sugarman S, Fornier M, Moynahan ME, et al. Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasible. Clin Breast Cancer 2008;8:418–24.
   PubMed Web of Science ®Google Scholar
• Dang C, Fornier M, Sugarman S, Troso-Sandoval T, Lake D, D’Andrea G, et al. The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in her-2/neu overexpressed/amplified breast cancer. J Clin Oncol 2008;26:1216–22.
   PubMed Web of Science ®Google Scholar
• Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of intergroup trial c9741/cancer and leukemia group b trial 9741. J Clin Oncol 2003;21:1431–9.
   PubMed Web of Science ®Google Scholar
• Dale DC. Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs 2002;62(Suppl 1): 1–15.
   PubMed Web of Science ®Google Scholar
• Mey UJ, Maier A, Schmidt-Wolf IG, Ziske C, Forstbauer H, Banat GA, et al. Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma. Support Care Cancer 2007;15:877–84.
   PubMed Web of Science ®Google Scholar
• Brusamolino E, Rusconi C, Montalbetti L, Gargantini L, Uziel L, Pinotti G, et al. Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: A phase II study of feasibility and toxicity. Haematologica 2006;91:496–502.
   PubMed Web of Science ®Google Scholar
• Tolaney SM, Partridge AH, Sheib RG, Burstein HJ, Winer EP. Pneumocystis carinii pneumonia during dose-dense chemotherapy for breast cancer. J Clin Oncol 2006;24:5330–1.
   PubMed Web of Science ®Google Scholar
• Semb KA, Aamdal S, Oian P. Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol 1998; 16:3426–32.
   PubMed Web of Science ®Google Scholar
• Piccart MJ, Klijn J, Paridaens R, Nooij M, Mauriac L, Coleman R, et al. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: Final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol 1997;15: 3149–55.
   PubMed Web of Science ®Google Scholar
• Khan A, McNally D, Tutschka PJ, Bilgrami S. Paclitaxel-induced acute bilateral pneumonitis. Ann Pharmacother 1997;31:1471–4.
   PubMed Web of Science ®Google Scholar
• Ramanathan RK, Reddy VV, Holbert JM, Belani CP. Pulmonary infiltrates following administration of paclitaxel. Chest 1996;110:289–92.
   PubMed Web of Science ®Google Scholar
• Fujimori K, Yokoyama A, Kurita Y, Uno K, Saijo N. Paclitaxel-induced cell-mediated hypersensitivity pneumonitis. Diagnosis using leukocyte migration test, bronchoalveolar lavage and transbronchial lung biopsy. Oncology 1998;55:340–4.
   PubMed Web of Science ®Google Scholar
• Goldberg HL, Vannice SB. Pneumonitis related to treatment with paclitaxel. J Clin Oncol 1995;13:534–5.
   PubMed Web of Science ®Google Scholar